Comparison of acute and chronic glucose-lowering effect of CS-917, a fructose 1,6-bisphosphatase inhibitor, and metformin, in rat models of type 2 diabetes

被引：0
|
作者：
Yoshida, Taishi
Takahashi, Kanako
Nakashima, Ryutaro
Kanda, Shoichi
Okuno, Akira
机构：
来源：
DIABETES | 2006年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A139 / A139
页数：1
相关论文
共 47 条
  • [41] Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents
    Tanaka, Atsushi
    Toyoda, Shigeru
    Imai, Takumi
    Shiina, Kazuki
    Tomiyama, Hirofumi
    Matsuzawa, Yasushi
    Okumura, Takahiro
    Kanzaki, Yumiko
    Onishi, Katsuya
    Kiyosue, Arihiro
    Nishino, Masami
    Sakata, Yasushi
    Node, Koichi
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [42] Islet-independent mechanisms contribute to the glucose-lowering effect of acute DPP-4 inhibition in healthy non diabetic and type 2 diabetes subjects after mixed meal intake
    Alsalim, W.
    Omar, B.
    Ahren, B.
    DIABETOLOGIA, 2015, 58 : S393 - S393
  • [43] COMPARISON OF THE EFFECTIVENESS OF SODIUM-GLUCOSE COUNTERSPOTTER 2 (SGLT-2) INHIBITOR THERAPY REGIMENS WITH METFORMIN AND DPP-4 INHIBITOR IN PATIENTS WITH STAGE 1-3 CHRONIC KIDNEY DISEASE ASSOCIATED WITH TYPE 2 DIABETES MELLITUS
    Khaydarova, F. A.
    Teshabekova, M. K.
    Aikhodgaeva, M. A.
    INTERNATIONAL JOURNAL OF EARLY CHILDHOOD SPECIAL EDUCATION, 2022, 14 (02) : 8129 - 8138
  • [44] A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study
    Ryang, Soree
    Kim, Sang Soo
    Bae, Ji Cheol
    Han, Ji Min
    Kwon, Su Kyoung
    Kim, Young Il
    Nam-Goong, Il Seong
    Kim, Eun Sook
    Kim, Mi-Kyung
    Lee, Chang Won
    Yoo, Soyeon
    Koh, Gwanpyo
    Kwon, Min Jeong
    Park, Jeong Hyun
    Kim, In Joo
    DIABETES OBESITY & METABOLISM, 2022, 24 (09): : 1800 - 1809
  • [45] Comparison of GLP-1 receptor agonists and other Glucose-Lowering agents on cardiovascular outcomes in individuals with type 2 diabetes and Obesity: A Spanish Real-World Population-Based study
    Palanca, Ana
    Ampudia-Blasco, F. Javier
    Calderon, Jose Miguel
    Sauri, Inmaculada
    Martinez-Hervas, Sergio
    Trillo, Jose Luis
    Redon, Josep
    Real, Jose T.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 207
  • [46] Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use
    Tsai, Chia-Jen
    Tsao, Cheng-Feng
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (11):
  • [47] Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease
    Tsukamoto, Shunichiro
    Kobayashi, Kazuo
    Toyoda, Masao
    Tone, Atsuhito
    Kawanami, Daiji
    Suzuki, Daisuke
    Tsuriya, Daisuke
    Machimura, Hideo
    Shimura, Hidetoshi
    Wakui, Hiromichi
    Takeda, Hiroshi
    Yokomizo, Hisashi
    Takeshita, Kei
    Chin, Keiichi
    Kanasaki, Keizo
    Miyauchi, Masaaki
    Saburi, Masuo
    Morita, Miwa
    Yomota, Miwako
    Kimura, Moritsugu
    Hatori, Nobuo
    Nakajima, Shinichi
    Ito, Shun
    Murata, Takashi
    Matsushita, Takaya
    Furuki, Takayuki
    Hashimoto, Takuya
    Umezono, Tomoya
    Muta, Yoshimi
    Takashi, Yuichi
    Tamura, Kouichi
    DIABETES OBESITY & METABOLISM, 2024, 26 (08): : 3248 - 3260
12345